CN120129535A - 组织因子抗体-药物缀合物及其用途 - Google Patents

组织因子抗体-药物缀合物及其用途 Download PDF

Info

Publication number
CN120129535A
CN120129535A CN202380076310.9A CN202380076310A CN120129535A CN 120129535 A CN120129535 A CN 120129535A CN 202380076310 A CN202380076310 A CN 202380076310A CN 120129535 A CN120129535 A CN 120129535A
Authority
CN
China
Prior art keywords
substituted
alkyl
amino acid
aryl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380076310.9A
Other languages
English (en)
Chinese (zh)
Inventor
罗宾·M·巴菲尔德
迈辛·鲍宗
佩妮罗普·M·德雷克
西玛·坎塔克
布莱恩·艾伦·孟德尔颂
蒂芬妮·恩苏蓝吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CN120129535A publication Critical patent/CN120129535A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380076310.9A 2022-09-07 2023-09-06 组织因子抗体-药物缀合物及其用途 Pending CN120129535A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263404447P 2022-09-07 2022-09-07
US63/404,447 2022-09-07
US202363498233P 2023-04-25 2023-04-25
US63/498,233 2023-04-25
PCT/US2023/073516 WO2024054821A2 (fr) 2022-09-07 2023-09-06 Conjugués anticorps-médicament de facteur tissulaire et leurs utilisations

Publications (1)

Publication Number Publication Date
CN120129535A true CN120129535A (zh) 2025-06-10

Family

ID=90191921

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380076310.9A Pending CN120129535A (zh) 2022-09-07 2023-09-06 组织因子抗体-药物缀合物及其用途

Country Status (15)

Country Link
EP (1) EP4583922A2 (fr)
JP (1) JP2025530129A (fr)
KR (1) KR20250060248A (fr)
CN (1) CN120129535A (fr)
AU (1) AU2023338206A1 (fr)
CA (1) CA3265517A1 (fr)
CL (1) CL2025000595A1 (fr)
CO (1) CO2025003047A2 (fr)
CR (1) CR20250074A (fr)
DO (1) DOP2025000050A (fr)
IL (1) IL319205A (fr)
MX (1) MX2025002614A (fr)
PE (1) PE20251256A1 (fr)
TW (1) TW202423991A (fr)
WO (1) WO2024054821A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024358957A1 (en) * 2023-10-13 2026-04-02 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020007077A (es) * 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
AU2022207454A1 (en) * 2021-01-15 2023-06-22 R.P. Scherer Technologies, Llc Camptothecine antibody-drug conjugates and methods of use thereof
TW202408585A (zh) * 2022-05-13 2024-03-01 美商艾克塞里克斯公司 5t4抗體-藥物結合物及其用途

Also Published As

Publication number Publication date
CA3265517A1 (fr) 2024-03-14
CO2025003047A2 (es) 2025-03-27
KR20250060248A (ko) 2025-05-07
IL319205A (en) 2025-04-01
CR20250074A (es) 2025-04-10
CL2025000595A1 (es) 2025-05-02
JP2025530129A (ja) 2025-09-11
EP4583922A2 (fr) 2025-07-16
TW202423991A (zh) 2024-06-16
DOP2025000050A (es) 2025-04-08
WO2024054821A2 (fr) 2024-03-14
WO2024054821A3 (fr) 2024-04-11
PE20251256A1 (es) 2025-05-06
MX2025002614A (es) 2025-04-02
AU2023338206A1 (en) 2025-03-06

Similar Documents

Publication Publication Date Title
CN113874046B (zh) 用于抗体-药物缀合物的含有糖苷的肽接头
CN120571033A (zh) 5t4抗体-药物缀合物及其用途
KR20240040098A (ko) 넥틴-4에 특이적인 항체 및 항체 접합체 및 이의 사용방법
CN120129535A (zh) 组织因子抗体-药物缀合物及其用途
TW202517682A (zh) 介白素-13受體次單元α-2抗體-藥物結合物及其用途
CN121752598A (zh) 酪氨酸蛋白激酶膜受体1 (ror1)抗体-药物缀合物和其用途
TW202510912A (zh) 可活化之酪胺酸-蛋白質激酶膜受體(ror)抗體-藥物結合物及其用途
CN118339165A (zh) 抗体-药物缀合物及其使用方法
CN120282965A (zh) 黏蛋白-1特异性抗体缀合物及其使用方法
CN117279662A (zh) 用于抗体-药物缀合物的支链接头和其使用方法
CN118119644A (zh) 具有人源化框架区的抗体
CN118076390A (zh) 肿瘤相关钙信号转导因子2(tacstd2)抗体-美登素缀合物及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination